10-21-2002

curasan receives pan-European approval for Cerasorb® block forms

curasan AG (WKN 549 453) has received EC certification for Cerasorb® block forms. With immediate effect, this product has been approved throughout Europe for unlimited use as a bone augmentation material in bone defects. Thus, curasan has extended its product portfolio in the area of bone regeneration by adding a broad range of block forms based on the proven Cerasorb® beta-Tricalciumphosphate synthetic ceramic ...

08-05-2002

curasan continues to grow despite weak economy

Revenue growth and lower costs

Kleinostheim, August 5, 2002 - According to preliminary figures, curasan AG (WKN: 549453), specialists in regenerative medicine, have succeeded in emulating their performance of Q1/2002 in the first half of 2002, as planned. Revenues increased by 20% to EUR7.16 million (previous year: EUR5.95m) ...

07-22-2002

curasan active in China

Performance of studies, registration of Cerasorb® expected in 2003

As curasan AG announced today, important steps were taken to start the distribution of their lead product Cerasorb® in China around end of next year ...

05-06-2002

curasan AG announces its preliminary results for Q1/2002:

Revenues increase by 25 per cent

Kleinostheim, 6 May 2002 - According to preliminary figures, curasan AG, a German company specialising in regenerative medicine, was able to increase its revenues by 25% in the first quarter of fiscal 2002, to EUR3.5 (2.8 in Q1/2001) million. The consolidated net loss for the period is expected to amount to EUR0.7 (0.4) million ...

03-21-2002

FDA approval for Cerasorb® in the US

curasan AG - specialists in regenerative biomedicine - have received 510(k) approval from the FDA (US Food and Drug Administration) for the use of the synthetic bone regeneration material Cerasorb® in the entire skeletal system. Cerasorb® is applied to bone defects; it is then fully resorbed and replaced by natural bone. The market volume for bone replacement and bone regeneration material was estimated at US$390 million in 2001 ...

03-11-2002

curasan gains access to the US market

Kleinostheim, March 11, 2002 - Curasan AG (WKN 549 453) - specialists in regenerative biomedicine - have exercised their option agreement concluded 14 months ago with the US-based firm Miter Inc, Warsaw, IN, and today acquired regulatory approval for the medical products Augmen™ and Peri-Oss™. Augmen™ and Peri-Oss™ have been approved by the US authorities as so-called PMA products (Pre-Marketing Approval products). They are related to curasan's bone substitute material Cerasorb® ...

01-24-2002

Revenue increases by more than 10%, to EUR12.02m

Organic growth and cost management are the main focus for 2002

According to preliminary figures for fiscal 2001, curasan AG was able to increase its revenues by 10.4 per cent to EUR12.02 million (revenues for year prior: EUR10.89m). The consolidated net loss is expected to be higher than in the preceding year ...